Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker.

Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M.

Oncotarget. 2017 Jun 13;8(24):39711-39726. doi: 10.18632/oncotarget.14410.

2.

Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations.

Eliyakin N, Postaci H, Baskin Y, Kozacioğlu Z.

Rare Tumors. 2015 Dec 29;7(4):5982. doi: 10.4081/rt.2015.5982. eCollection 2015 Dec 29.

3.

Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.

Matsumura Y, Umemura S, Ishii G, Tsuta K, Matsumoto S, Aokage K, Hishida T, Yoshida J, Ohe Y, Suzuki H, Ochiai A, Goto K, Nagai K, Tsuchihara K.

J Cancer Res Clin Oncol. 2015 Dec;141(12):2159-70. doi: 10.1007/s00432-015-1989-z. Epub 2015 May 20.

4.

Synchronous poorly-differentiated neuroendocrine carcinoma and gastrointestinal stromal tumor of the stomach: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA.

Ding J, Sun P, Cai XY, Fei SH, Wu J, Qi YK, Liu ZB, Yuan L, He YJ, Song H, Chen WX.

Int J Clin Exp Pathol. 2014 Dec 1;7(12):9076-80. eCollection 2014.

5.

NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML.

J Natl Compr Canc Netw. 2014 Nov;12(11):1629-49.

6.
7.

Prognostic value of CD117 in cancer: a meta-analysis.

Zhao F, Chen Y, Wu Q, Wang Z, Lu J.

Int J Clin Exp Pathol. 2014 Feb 15;7(3):1012-21. eCollection 2014.

8.

Small cell carcinoma of the urinary bladder.

Terada T.

Int J Clin Exp Pathol. 2012;5(6):596-600. Epub 2012 Jul 17.

9.

Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.

Capodanno A, Boldrini L, Alì G, Pelliccioni S, Mussi A, Fontanini G.

Oncol Rep. 2012 Nov;28(5):1559-66. doi: 10.3892/or.2012.2017. Epub 2012 Sep 4.

10.
11.

Esophageal combined carcinomas: Immunohoistochemical and molecular genetic studies.

Terada T, Maruo H.

World J Gastroenterol. 2012 Apr 7;18(13):1545-51. doi: 10.3748/wjg.v18.i13.1545.

12.

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

Dy GK, Hillman SL, Rowland KM Jr, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE, Adjei AA; North Central Cancer Treatment Group Study N0326.

Cancer. 2010 Dec 15;116(24):5686-93. doi: 10.1002/cncr.25448.

13.

Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy.

Sakakura C, Hagiwara A, Soga K, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Yamaoka N, Sagara Y, Yamagishi H.

World J Gastroenterol. 2006 May 7;12(17):2793-7.

14.

Large cell neuroendocrine carcinoma of the ampulla of Vater with glandular differentiation.

Cheng SP, Yang TL, Chang KM, Liu CL.

J Clin Pathol. 2004 Oct;57(10):1098-100. Review.

Supplemental Content

Support Center